TopoGEN provides innovative reagents and kits for topoisomerase research and mechanism-based drug development in cancer. Kits are available to assay for topoisomerases (I, II, IV and gyrase) and Tdp1, to measure topo/DNA interactions in vivo and to identify new topoisomerase drugs. TopoGEN also offer a complete line of DNA substrates topo inhibitors, antibodies, and kit replenishment reagents.

• Replacement components and topoisomerase inhibitors - for use with kits and research applications involving topoisomerases
• TopoGEN kits - assay kits, screening kits, precipitation kits, link kits, unwinding kits, immunofluorescence kits and immunoprecipitation kits
• Enzymes - sensitive to DNA quality
• Antibodies
• DNA - screened to support Topoisomerase (and gyrase) activity

Featured Products and Services

• Kinetoplast DNA (catenated) - The ideal Topo II Substrate [TG2013-2]
• Supercoiled pBR322 DNA - excellent plasmid choice for assaying any topoisomerase [TG2036-2]
• Human Topoisomerase I - Wild Type Protein overexpressed in baculovirus [TG2005H-RC1]
• E. coli DNA Gyrase (Type II Topoisomerase) - holoenzyme containing both A,B subunits [TG2000G-1]
• Topoisomerase I Assay Kit - easily interpret topo I activity [TG1015-1]
• Topoisomerase I Drug Screening Kit - model drug action with novel topo I active agents [TG1018-1]
• Polyclonal Antibodies to Human Topo I - [TG2012] and [TG2012-2]

TopoGEN Screening Services

TopoGEN offers a custom screening program that utilizes the kits, enzymes, and reagents they have developed and that their customers have used with success over the past 20 years. Now you can shorten your project timeline and commit their staff of experts to your compound screening pursuits. They can accomplish in days what may take weeks or months for other labs. You simply provide them with your compounds in either a dry or stabilized state at a known concentration or weight. They offer three levels of custom services for topoisomerase I, II, IV, E. coli DNA Gyrase and S. aureus DNA Gyrase. In most cases, the customer knows whether an inhibitor vs. poison is associated with the compound to be tested. This makes custom screening cost effective since it narrows the screening process.

All screening contracts conclude with a final technical write-up reviewed and signed by their President and CEO, with an option for follow-up evaluations by their scientists if necessary.